Enumeral Biomedical (ENUM) 0.8000 $ENUM
Enumeral Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Thu Mar 19, 4:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2014.
MRK: 57.25 (-0.18)
Enumeral to Present Corporate and Program Overview at March Conferences
Business Wire - Tue Mar 17, 6:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present a corporate overview at BioCentury's 22nd Annual Future Leaders in the Biotech Industry conference on March 20, 2015 at 4:00 p.m. EDT. The presentation will be followed by a breakout session. The meeting is being held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast of the presentation will be accessible on the Events page of Enumeral's website. It will be archived and available for replay for at least 60 days.
Enumeral and the Ragon Institute of MGH, MIT and Harvard to Research Human Mucosal Immunology with Immune Profiling System
Business Wire - Mon Mar 09, 6:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University as part of Enumeral's Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed in the laboratory of Douglas S. Kwon, M.D., Ph.D., Assistant Professor of Medicine at the Ragon Institute. Enumeral recently announced an agreement to place the system with Memorial Sloan-Kettering Cancer Center.
Enumeral to Present at Sachs Associates Cancer Bio Partnering & Investment Forum
Business Wire - Thu Feb 19, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the Sachs Associates Cancer Bio Partnering & Investment Forum on February 23, 2015 at 12:00 p.m. EST. The meeting is being held at the New York Academy of Sciences in New York City.
Enumeral and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology With Advanced Prototype System for Human Tissue Immuno-Oncology Profiling
Business Wire - Mon Jan 12, 7:02AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with Memorial Sloan Kettering (MSK) Cancer Center as part of Enumeral's Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer.
Enumeral to Present at Upcoming Conferences in January
Business Wire - Thu Jan 08, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the following conferences:
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 3.12 (-0.03), MRK: 57.25 (-0.18)
Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform
Business Wire - Thu Dec 18, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck.
MRK: 57.25 (-0.18)
Enumeral: An Undiscovered And Undervalued Biotechnology Company
Tony Schwartz, PhD - at Seeking Alpha - Sat Dec 06, 7:00AM CST
Enumeral Appoints Robert L. Van Nostrand to its Board of Directors
Business Wire - Thu Dec 04, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today it has appointed Robert L. Van Nostrand to its Board of Directors. Mr. Van Nostrand is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including Chief Compliance Officer, Chief Financial Officer and Chief Accounting Officer. OSI Pharmaceuticals, prior to its acquisition by Astellas Pharma, was a public company that, along with its partner Genentech, developed and commercialized the oncology drug, Tarceva(R).
Enumeral Reports Third Quarter 2014 Financial Results
Business Wire - Fri Nov 14, 3:35PM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company" , today reported its financial results for the three and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission.
Enumeral Appoints Isabel Chiu, Ph.D., as Vice President of Translational and Clinical Sciences
Business Wire - Tue Oct 21, 7:01AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that M. Isabel Chiu, Ph.D., has been appointed Vice President of Translational and Clinical Sciences. Dr. Chiu brings over 20 years of scientific, academic and industry experience in shaping biotechnology programs from research to late-stage development. She is responsible for developing and implementing Enumeral's internal and external translational programs using human patient-derived tissue samples in ex vivo preclinical trials. Dr. Chiu oversees the operational, program management and strategic initiatives to support these goals.
Enumeral Appoints Kevin Sarney, CPA, as Vice President of Finance and Chief Accounting Officer
Business Wire - Mon Sep 15, 7:01AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Mr. Sarney brings significant finance, accounting, operations and SEC reporting experience to Enumeral having served over 15 years in the life science industry in both early-stage and publicly traded companies.
Harris & Harris Group Portfolio Company Enumeral Biomedical Completes Equity Offering and Public Listing
GlobeNewswire - Mon Aug 04, 7:57AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that its portfolio company, Enumeral Biomedical Corp., completed a reverse merger of the company into a publicly traded shell company simultaneous with the close of a $21.55 million equity round of financing. The surviving entity will be called Enumeral Biomedical Holdings, Inc. ("Enumeral" (formerly known as Cerulean Group, Inc.), and be traded on the OTC Market under the symbol "ENUM." Montrose Capital Partners led the round of financing, Intuitive Venture Partners acted as exclusive financial advisor and EDI Financial acted as the lead placement agent. Harris & Harris Group invested $1.5 million in this round of financing alongside other current investors including Allan Rothstein of Hedge Capital Partners and a member of the board of directors of Enumeral. Following this transaction, Harris & Harris Group will own approximately 15 percent of the outstanding securities of publicly traded Enumeral.
TINY: 3.12 (-0.03)
Enumeral Biomedical Raises $21.5 Million from New and Current Investors, Begins Public Trading
Business Wire - Mon Aug 04, 6:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral" today announced the completion of a merger between Enumeral Biomedical Corp. and a subsidiary of Enumeral Biomedical Holdings, Inc., formerly known as Cerulean Group, Inc. Coinciding with the merger, Enumeral has closed on $21.5 million in a private placement financing. Shares of the Company's common stock are currently quoted on the OTC Markets under the symbol "ENUM."
Enumeral Reports Fourth Quarter and Year-End 2014 Financial Results
Business Wire - Thu Mar 19, 4:30PM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, a biotechnology company focused on the discovery and development of novel therapeutics that help the immune system fight cancer and other diseases, today announced its financial results for the three months and full year ended December 31, 2014. MRK: 57.25 (-0.18)
Enumeral to Present Corporate and Program Overview at March Conferences
Business Wire - Tue Mar 17, 6:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present a corporate overview at BioCentury's 22nd Annual Future Leaders in the Biotech Industry conference on March 20, 2015 at 4:00 p.m. EDT. The presentation will be followed by a breakout session. The meeting is being held at the Millennium Broadway Hotel & Conference Center in New York. A live webcast of the presentation will be accessible on the Events page of Enumeral's website. It will be archived and available for replay for at least 60 days.
Enumeral and the Ragon Institute of MGH, MIT and Harvard to Research Human Mucosal Immunology with Immune Profiling System
Business Wire - Mon Mar 09, 6:30AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT) and Harvard University as part of Enumeral's Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed in the laboratory of Douglas S. Kwon, M.D., Ph.D., Assistant Professor of Medicine at the Ragon Institute. Enumeral recently announced an agreement to place the system with Memorial Sloan-Kettering Cancer Center.
Enumeral to Present at Sachs Associates Cancer Bio Partnering & Investment Forum
Business Wire - Thu Feb 19, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the Sachs Associates Cancer Bio Partnering & Investment Forum on February 23, 2015 at 12:00 p.m. EST. The meeting is being held at the New York Academy of Sciences in New York City.
Enumeral and Memorial Sloan Kettering Cancer Center to Research Cancer Immunology With Advanced Prototype System for Human Tissue Immuno-Oncology Profiling
Business Wire - Mon Jan 12, 7:02AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that the company signed an agreement with Memorial Sloan Kettering (MSK) Cancer Center as part of Enumeral's Phase II Small Business Innovation Research (SBIR) contract with the National Cancer Institute (NCI). Enumeral is developing an advanced, automated prototype system for human tissue immuno-oncology profiling, which will be deployed at MSK in the laboratory of Jedd D. Wolchok, M.D., Ph.D., Chief of Melanoma and Immunotherapeutics Service, Lloyd J. Old/Ludwig Chair in Clinical Investigation Department of Medicine and Ludwig Center, at Memorial Sloan Kettering Cancer Center. Dr. Wolchok played a critical role in the clinical development of ipilimumab and nivolumab, immunotherapies which represent a transformational advancement in the treatment of cancer.
Enumeral to Present at Upcoming Conferences in January
Business Wire - Thu Jan 08, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today that Arthur H. Tinkelenberg, Ph.D., President and Chief Executive Officer, is scheduled to present at the following conferences:
Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck
GlobeNewswire - Mon Dec 22, 11:28AM CST
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, notes that its publicly traded portfolio company, Enumeral Biomedical Holdings, Inc., announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck. Enumeral's human-driven immune profiling platform may increase the probability of finding rare immune cells associated with disease or drug response through improved efficiency and sensitivity. Studying rare cells obtained directly from human patients for their functional responses can potentially lead to identification of those patients responsive to a therapy, while elucidating the underlying cellular basis for such a response. Under the terms of the agreement, Enumeral will receive R&D funding and is eligible to receive undisclosed future milestone payments if certain goals are achieved. Merck has exclusive rights to data related to its proprietary compounds that are generated from the studies. You may access Enumeral's press release at http://www.enumeral.com/news-events/pr-2014-12-18.php.
TINY: 3.12 (-0.03), MRK: 57.25 (-0.18)
Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform
Business Wire - Thu Dec 18, 7:01AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), today announced that it has signed an oncology-focused collaborative study agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary. The collaborators will use Enumeral's human approach to interrogating the tumor microenvironment in colorectal cancer tissues obtained directly from patients in order to identify functional cellular responses to immuno-oncology therapies being developed by Merck.
MRK: 57.25 (-0.18)
Enumeral: An Undiscovered And Undervalued Biotechnology Company
Tony Schwartz, PhD - at Seeking Alpha - Sat Dec 06, 7:00AM CST
Enumeral Appoints Robert L. Van Nostrand to its Board of Directors
Business Wire - Thu Dec 04, 7:00AM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM), announced today it has appointed Robert L. Van Nostrand to its Board of Directors. Mr. Van Nostrand is a seasoned biotechnology executive with an extensive background in finance, operations and accounting in public biotechnology companies in all stages of development. For 21 years, he served in executive leadership positions at OSI Pharmaceuticals, including Chief Compliance Officer, Chief Financial Officer and Chief Accounting Officer. OSI Pharmaceuticals, prior to its acquisition by Astellas Pharma, was a public company that, along with its partner Genentech, developed and commercialized the oncology drug, Tarceva(R).
Enumeral Reports Third Quarter 2014 Financial Results
Business Wire - Fri Nov 14, 3:35PM CST
Enumeral Biomedical Holdings, Inc. (OTCQB: ENUM) ("Enumeral" or the "Company"
, today reported its financial results for the three and nine months ended September 30, 2014. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission. Enumeral Appoints Isabel Chiu, Ph.D., as Vice President of Translational and Clinical Sciences
Business Wire - Tue Oct 21, 7:01AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that M. Isabel Chiu, Ph.D., has been appointed Vice President of Translational and Clinical Sciences. Dr. Chiu brings over 20 years of scientific, academic and industry experience in shaping biotechnology programs from research to late-stage development. She is responsible for developing and implementing Enumeral's internal and external translational programs using human patient-derived tissue samples in ex vivo preclinical trials. Dr. Chiu oversees the operational, program management and strategic initiatives to support these goals.
Enumeral Appoints Kevin Sarney, CPA, as Vice President of Finance and Chief Accounting Officer
Business Wire - Mon Sep 15, 7:01AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM), today announced that Kevin Sarney, CPA, has been appointed Vice President of Finance and Chief Accounting Officer. Mr. Sarney brings significant finance, accounting, operations and SEC reporting experience to Enumeral having served over 15 years in the life science industry in both early-stage and publicly traded companies.
Harris & Harris Group Portfolio Company Enumeral Biomedical Completes Equity Offering and Public Listing
GlobeNewswire - Mon Aug 04, 7:57AM CDT
Harris & Harris Group, Inc. (Nasdaq:TINY), an investor in transformative companies enabled by disruptive science, today announced that its portfolio company, Enumeral Biomedical Corp., completed a reverse merger of the company into a publicly traded shell company simultaneous with the close of a $21.55 million equity round of financing. The surviving entity will be called Enumeral Biomedical Holdings, Inc. ("Enumeral"
(formerly known as Cerulean Group, Inc.), and be traded on the OTC Market under the symbol "ENUM." Montrose Capital Partners led the round of financing, Intuitive Venture Partners acted as exclusive financial advisor and EDI Financial acted as the lead placement agent. Harris & Harris Group invested $1.5 million in this round of financing alongside other current investors including Allan Rothstein of Hedge Capital Partners and a member of the board of directors of Enumeral. Following this transaction, Harris & Harris Group will own approximately 15 percent of the outstanding securities of publicly traded Enumeral. TINY: 3.12 (-0.03)
Enumeral Biomedical Raises $21.5 Million from New and Current Investors, Begins Public Trading
Business Wire - Mon Aug 04, 6:00AM CDT
Enumeral Biomedical Holdings, Inc. (OTCQB:ENUM) ("Enumeral"
today announced the completion of a merger between Enumeral Biomedical Corp. and a subsidiary of Enumeral Biomedical Holdings, Inc., formerly known as Cerulean Group, Inc. Coinciding with the merger, Enumeral has closed on $21.5 million in a private placement financing. Shares of the Company's common stock are currently quoted on the OTC Markets under the symbol "ENUM." 
